Provided by Tiger Fintech (Singapore) Pte. Ltd.

Soleno Therapeutics

70.25
+0.25000.36%
Post-market: 70.250.00000.00%18:22 EDT
Volume:1.10M
Turnover:76.58M
Market Cap:3.22B
PE:-16.05
High:70.36
Open:69.79
Low:68.27
Close:70.00
Loading ...

Company Profile

Company Name:
Soleno Therapeutics
Exchange:
NASDAQ
Establishment Date:
1999
Employees:
92
Office Location:
100 Marine Parkway,Suite 400,Redwood City,California,United States
Zip Code:
94065
Fax:
650 213 8383
Introduction:
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Directors

Name
Position
Anish Bhatnagar
President, Chief Executive Officer and Director
Ernest Mario
Chairman
Edgar G. Engleman
Director
James Glasheen
Director
Mahendra G. Shah
Director
Rajen Dalal
Director
Steinar J. Englesen
Director
Stephen Kirnon
Director
Stuart Collinson
Director
William G. Harris
Director

Shareholders

Name
Position
Anish Bhatnagar
President, Chief Executive Officer and Director
Anthony Wondka
Senior Vice President of Research and Development
David D. O'Toole
Senior Vice President, Chief Financial Officer